Operating
Operating lease right-of-use asset amortization
Neurocrine Biosciences Operating lease right-of-use asset amortization decreased by 59.1% to $2.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 62.5%, from $7.20M to $2.70M.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ3 2024
Last reportedQ1 2026May 5, 2026
How to read this metric
Stable levels reflect a consistent lease portfolio, while spikes may indicate changes in lease terms or new major lease agreements.
Detailed definition
This represents the non-cash amortization of the right-of-use asset created under lease accounting standards. It reflect...
Peer comparison
Standard for companies with significant leased real estate footprints.
Metric ID:
operating_operating_lease_right_of_use_asset_amortizatio_94fda1Historical Data
5 periods
| Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $300.00K | $7.20M | $7.10M | $6.60M | $2.70M |
| QoQ Change | — | >999% | -1.4% | -7.0% | -59.1% |
| YoY Change | — | — | — | >999% | -62.5% |
Range$300.00K – $7.20M
CAGR+800.0%
Avg YoY Growth>999%
Median YoY Growth>999%
Current Streak3 quarters decline
Operating lease right-of-use asset amortization at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's operating lease right-of-use asset amortization?
- Neurocrine Biosciences (NBIX) reported operating lease right-of-use asset amortization of $2.70M in Q1 2026.
- How has Neurocrine Biosciences's operating lease right-of-use asset amortization changed year-over-year?
- Neurocrine Biosciences's operating lease right-of-use asset amortization decreased by 62.5% year-over-year, from $7.20M to $2.70M.
- What does operating lease right-of-use asset amortization mean?
- The non-cash expense representing the consumption of leased property rights over time.